NASDAQ : CING
Cingulate Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 4.98 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 72.42M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 73.15M |
| Enterprise Value | 51.03M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 14.54M |
| Shares Outstanding | 14.54M |
| Shares Change (YoY) | +167.56% |
| Shares Change (QoQ) | +34.86% |
| Owned by Insiders (%) | 0.92% |
| Owned by Institutions (%) | 28.39% |
| Float | 14.20M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 6.77 |
| PB Ratio | 2.95 |
| P/TBV Ratio | 3.09 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.50 |
| Quick Ratio | 3.30 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -11.47 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -198.74% |
| Return on Assets (ROA) | -66.94% |
| Return on Invested Capital (ROIC) | -74.43% |
| Return on Capital Employed (ROCE) | -101.98% |
| Weighted Average Cost of Capital (WACC) | 1.62% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.06M |
| Employee Count | 14 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.88 |
| 52-Week Price Change | +30.83% |
| 50-Day Moving Average | 5.01 |
| 200-Day Moving Average | 5.44 |
| Relative Strength Index (RSI) | 51.04 |
| Average Volume (20 Days) | 116,196 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.02M |
| Short Previous Month | 1.03M |
| Short % of Shares Out | 6.99% |
| Short % of Float | 7.16% |
| Short Ratio (days to cover) | 11.08 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | -8.52M |
| Operating Income | -24.92M |
| Pretax Income | -28.80M |
| Net Income | -28.81M |
| EBITDA | -24.47M |
| EBIT | -24.92M |
| Earnings Per Share (EPS) | -$3.28 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 28.40M |
| Total Debt | 6.29M |
| Net Cash | 22.11M |
| Net Cash Per Share | $1.52 |
| Equity (Book Value) | 23.47M |
| Book Value Per Share | 1.69 |
| Working Capital | 21.58M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -20.65M |
| Capital Expenditures | -284,476 |
| Depreciation & Amortization | 448,042 |
| Net Borrowing | 5.34M |
| Free Cash Flow | -20.94M |
| FCF Per Share | -$1.44 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -167.56% |
| Shareholder Yield | -167.56% |
| Earnings Yield | -65.20% |
| FCF Yield | -28.91% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $21.20 |
| Price Target Difference | 321.47% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Aug 9, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:12 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |